The USAID MVDP and partners had two main thrusts towards a children’s vaccine:
1. Protein vaccines with Walter Reed Army Institute of Research (WRAIR), the Malaria Vaccine Initiative (MVI) at PATH, GSK and NIH; and
2. Viral vectored vaccines with the Naval Medical Research Institute, and MVI.
There were insufficient human and financial resources in any one institution to support a robust malaria vaccine development program. It was only through alliances that the task could be accomplished. Thus, for the most advanced vaccine the alliance is developing, USAID funded the development of processes to make the vaccine at WRAIR, GSK provided the adjuvant, and the vaccine was being field tested by MVI and NIH.
|Value||USD 103 Million|